Kantar Health Blog

  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2013 --- Multiple Myeloma has had significant new advances in the past year, with the U.S. Food and Drug Administration (FDA) approval of Kyprolis® (carfilzomib, Onyx/Amgen) and the U.S. and European approvals of Pomalyst® (Imnovid® in Europe, pomalidomide, Celgene), both in the relapsed/refractory setting. The relapsed/refractory setting is poised for further evolution with the recently announced success of the PANORAMA-2 Phase III trial of panobinostat (LBH589, Novartis) and ongoing Phase III trials with numerous other promising agents.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2013 --- CLL is a disease of the elderly, with a median age of diagnosis at 71 in the U.S. and nearly 40% of patients older than 75 at the time of diagnosis. Standard treatment for “fit” patients is aggressive chemotherapy, but existing comorbidities in elderly patients frequently preclude use of these highly toxic regimens. Phase III trials are ongoing or recently completed for Arzerra, ibrutinib , and Gazyva.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ECC 2013 --- In recent years, angiogenesis inhibition, and VEGFR inhibition in particular, has been the most promising therapeutic target in advanced ovarian cancer, and the VEGF-targeted monoclonal antibody Avastin® (bevacizumab, Roche/Genentech) has been the major player in drug development for this tumor type. With Phase III trials conducted in multiple settings in ovarian cancer, Avastin has demonstrated a progression-free survival (PFS) benefit in first-line, recurrent platinum-sensitive, and recurrent platinum-resistant patients, and in the past two years, it has received regulatory approval in the European Union for use in the first-line/maintenance and recurrent platinum-sensitive settings.
    Continue Reading > | Go comment! | Share
  • The Next Showdown in BRAF-Mutant Melanoma

    by Stephanie Hawthorne | Sep 30, 2013
    Stephanie Hawthorne
    Oncology Conference Insight: ECC 2013 --- The melanoma field exploded two years ago, with the 2011 and 2012 approvals of Yervoy® (ipilimumab, Bristol-Myers Squibb) and Zelboraf® (vemurafenib, Genentech/Roche/Daiichi Sankyo). The approval of Zelboraf also ushered in the era of personalized medicine in melanoma, effectively segmenting the market in half – those patients with BRAF V600E mutation (approximately 44% of patients), and those without. In May 2013, the field expanded again following the FDA approvals of Tafinlar® (dabrafenib, GlaxoSmithKline) and Mekinist® (trametinib, GlaxoSmithKline), and one month later the European Medicines Agency (EMA) approval of Tafinlar, for treatment of BRAF-mutant unresectable or metastatic melanoma.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ECC 2013 --- Two late-breaking abstracts during the colorectal cancer sessions at the 2013 European Cancer Congress were centered on the anti-EGFR therapies Erbitux® (cetuximab, Bristol-Myers Squibb/Eli Lilly/Merck KGaA) and Vectibix® (panitumumab, Amgen/Takeda). Although the data probably won’t immediately change clinical practice, questions continue to arise. If answered favorably, these therapies could conceivably be utilized more strongly in KRAS wild-type patients.
    Continue Reading > | Go comment! | Share